NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors of NAD+ (nicotinamide adenine dinucleotide), a coenzyme required for cellular energy production, DNA repair, and NAD-dependent enzymatic processes essential to metabolic function. In human studies, both compounds increase circulating NAD+ after oral administration. However, clinical trials have not demonstrated that either NMN or NR is superior in aging-related outcomes, cognition, or long-term health effects.
- NMN and NR are both NAD+ precursors used by the body to support the production of NAD+ (nicotinamide adenine dinucleotide), a coenzyme involved in mitochondrial function, energy metabolism, DNA repair, and sirtuin activity.
- Both NMN and NR increase NAD+ levels in human studies, although the extent and consistency of this increase vary across trials and population groups.
- Clinical outcomes remain inconsistent, with no reliable evidence that either NMN or NR produces sustained or clinically meaningful improvements in aging, cognition, or metabolic health.
- Regulatory status differs between compounds, with NR consistently recognized as a dietary supplement ingredient in the United States, while NMN has experienced periods of regulatory uncertainty.
- No clear superiority has been established between NMN and NR based on current human clinical evidence.
What NMN and NR are and what they do in the body
NMN (nicotinamide mononucleotide) is a direct precursor in the NAD+ synthesis pathway, while NR (nicotinamide riboside) is a vitamin B3 derivative converted into NAD+ through the NAD+ salvage pathway. NAD+ is required for cellular energy production, DNA repair, and other essential cellular processes. As outlined by Yoshino et al. (2018), age-related decline in NAD+ has driven growing interest in both compounds as potential strategies to support NAD+ maintenance.1
NR is phosphorylated by nicotinamide riboside kinases (NRK1/NRK2) to form NMN, which then proceeds to NAD+ formation via NMN adenylation. NMN proceeds directly to NAD+ formation through a single adenylation step. Grozio et al. (2019) reported evidence from experimental models of a specific intestinal transporter for NMN (Slc12a8). No equivalent transporter-dependent uptake has been demonstrated for NR, showing different entry routes into the cell, even though both end up in the same final biosynthetic pathway.2
NAD+ concentrations decline in aged tissues due to increased consumption and reduced biosynthetic capacity. McReynolds et al. (2020) noted that the threshold at which this depletion translates into measurable physiological effects is tissue-dependent and remains undefined in current human evidence.3
Why NMN and NR are studied for aging and longevity
NMN and NR are being studied as potential interventions in aging because age-related decline begins at the cellular level, and NAD+ availability is linked to processes that decline with age, including mitochondrial function, sirtuin signaling, and DNA repair.
These age-related reductions in NAD+ levels have been observed across multiple tissues in animal models, while human data show variable changes across different tissues and study designs. Preclinical models have also reported that increasing NAD+ availability through NMN or NR can modify biomarkers of mitochondrial function and sirtuin activity in aged animals, findings that have driven interest in potential human relevance.3
The magnitude and functional consequences of NAD+ decline, however, remain incompletely defined across human tissues, and increased NAD+ biomarkers have not shown consistent functional effects on age-related clinical outcomes.
What human research actually shows
Direct human comparisons between NMN and NR are limited, with only a small number of head-to-head controlled datasets available to date, including the Nestlé Health Science trial and the University of Bergen study, each evaluating both compounds under their own distinct protocols.
In a randomized placebo-controlled trial conducted by Nestlé Health Science involving 65 healthy adults over 14 days, NMN and NR produced comparable increases in circulating NAD+ concentrations, while nicotinamide did not maintain the same effect. Both compounds increased systemic NAD+ through shared downstream metabolic processing involving nicotinic acid formation and entry into the Preiss–Handler pathway, as described by Christen et al. (2026), showing that both compounds reach NAD+ through the same metabolic route.4
The University of Bergen pharmacokinetic study from a phase I trial administering 1,200 mg/day of NMN or NR in healthy adults and individuals with Parkinson's disease showed that blood NAD+ levels plateaued after approximately two weeks, while cerebral NAD+ increases became detectable after around four weeks of sustained dosing. Responses varied between individuals, with no consistent influence of sex or disease status, and Berven et al. (2026) reported that sustained daily administration over two to four weeks is required to achieve stable NAD+ elevation, after which maintenance appears achievable with once-daily dosing.5 Independent NMN data further support these findings. In a randomized dose-dependent trial of healthy middle-aged adults, Yi et al. (2023) reported significant increases in blood NAD+ across all active NMN doses up to 900 mg daily, with good short-term tolerability and exploratory improvements in physical performance, extending the evidence for reliable NAD+ elevation beyond head-to-head comparisons.6
An earlier 10-week randomized trial by Yoshino et al. (2021) in postmenopausal women with prediabetes reported improved muscle insulin sensitivity following 250 mg/day NMN, although this finding has not been replicated in subsequent human studies and the trial's randomization has been questioned due to baseline lipid imbalance.7 In independent NR trials, a randomized crossover study in 30 healthy middle-aged and older adults found NR to be well tolerated with increases in NAD+ metabolism and exploratory signals toward reduced blood pressure and arterial stiffness, which Martens et al. (2018) classified as requiring further validation.8 Elhassan et al. (2019) further demonstrated that 1,000 mg NR daily for 21 days increased skeletal muscle NAD+ metabolites and reduced circulating inflammatory cytokines in aged men, without corresponding changes in mitochondrial energy production.9
A similar pattern has been observed in cognitive studies. Orr et al. (2024) reported a 2.6-fold increase in blood NAD+ following NR supplementation in older adults with mild cognitive impairment, without measurable improvement in cognition or other neurocognitive outcomes despite good tolerability.10 Over 24 weeks, a double-blind placebo-controlled trial of 2,000 mg NR daily in 58 participants with long-COVID showed substantial increases in NAD+ levels without significant between-group differences in fatigue, cognition, sleep quality, anxiety, or depression. Wu et al. (2025) reported exploratory within-group improvements at 10 weeks, although these were unadjusted for multiplicity and therefore limited in interpretive strength.11
Across available human studies, NMN and NR consistently elevate NAD+ across doses and populations, with head-to-head evidence indicating broadly equivalent biomarker effects. Functional outcomes, however, remain inconsistent and do not yet demonstrate a clear translation of NAD+ elevation into predictable clinical benefit.
Laboratory and animal research
Preclinical studies show NMN and NR increase intracellular NAD+ across cellular and animal models, with Ratajczak et al. (2016) demonstrating that extracellular NMN is converted to NR prior to cellular uptake, after which both enter the NAD+ salvage pathway through shared metabolic processing.12
Both compounds increase NAD+ in metabolically active tissues including liver, skeletal muscle, heart, kidney, and brain, with associated changes in mitochondrial function, redox balance, and NAD+-dependent stress response pathways reported across mammalian systems.
Tarantini et al. (2019) described improved cerebrovascular function, neurovascular coupling, and cerebral blood flow in aged mouse models following NMN administration, alongside enhanced mitochondrial efficiency linked to sirtuin-related regulation, while Ramanathan et al. (2022) noted that comparable brain NAD+ effects have not been demonstrated in humans despite rodent findings.13,14
ApoE knockout models show improved lipid metabolism and hepatic fat outcomes with NMN and NR, though Wang et al. (2025) report increased atherosclerotic burden under long-term exposure in specific conditions, reinforcing model, dose, and context dependence in preclinical metabolic effects.15
Human research
Both nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are established NAD+ precursors that consistently increase circulating NAD+ concentrations in humans. Although differences in pharmacokinetics and metabolic processing have been observed across head-to-head and independent trials, current evidence shows broadly equivalent effects on NAD+ elevation, with neither compound demonstrating a clear biomarker advantage.
Exploratory and post-hoc analyses have occasionally suggested improvements in outcomes such as physical performance, fatigue, or sleep quality. In randomized controlled trials, however, these effects have not been consistently reproduced, and evidence across broader cognitive, cardiovascular, and functional endpoints remains limited and inconsistent.
Dosing in research and real-world use
Across human studies, NMN and NR are administered within a broad range of 250–2,000 mg daily, with increases in circulating NAD+ observed throughout this dosing spectrum. However, available data do not establish a dose-dependent relationship with functional outcomes.
Blood NAD+ rises gradually over sustained supplementation, typically reaching a plateau after approximately two weeks.5 Cerebral NAD+ increases are slower, becoming measurable after about four weeks of continuous intake. Once steady state is achieved, once-daily dosing is sufficient to maintain elevated NAD+ levels in most participants.
Across studies, individual responses vary, reflecting differences in metabolism, baseline NAD+ status, and how the compounds are absorbed and processed.
How long it takes to affect NAD+ levels
Human pharmacokinetic data consistently show that increases in circulating NAD+ are not immediate but emerge over a defined supplementation window. In controlled trials using oral NMN or NR at 1,200 mg/day, blood NAD+ begins to rise within days and typically reaches a plateau after approximately 10–14 days of continuous administration.4,5
Brain NAD+ levels rise more slowly than those in circulation. Measurable increases in brain NAD+ are generally observed after around 3–4 weeks of sustained supplementation,5 indicating a delayed tissue-level response relative to circulating compartments.
Although increases in NAD+ are consistently observed across studies, these changes have not been reliably accompanied by consistent or meaningful improvements in clinical outcomes.
What people notice and what they don't
Across randomized trials, improvements in fatigue, cognition, sleep, mood, and cardiovascular markers have not been consistently observed despite reliable increases in NAD+ levels. In a long-COVID trial, NAD+ rose 2.6–3.1-fold with nicotinamide riboside without significant between-group differences in primary or secondary outcomes.11
Interindividual variability in NAD+ response is consistently observed across NMN and NR, reflecting differences in baseline physiology and metabolic processing. However, this variability does not reliably correspond to differences in functional outcomes.
Safety, side effects, and population cautions
In a 12-week placebo-controlled trial, Okabe et al. (2022) found no clinically meaningful changes in physiological or laboratory safety markers with NMN at 250 mg daily, alongside confirmed NAD+ elevation.16 In higher-dose NR trials, including phase I and Parkinson's disease cohorts, no moderate or severe adverse events were reported, only mild transient effects in some participants, with preserved methyl donor status despite a small transient rise in serum homocysteine.5
Both NMN and NR converge on nicotinamide as a downstream metabolite, and Hwang and Song (2020) identify theoretical risk for methyl donor perturbation and epigenetic disruption under sustained high-dose exposure. No human trial has demonstrated this as a clinical outcome.17
Zhang et al. (2023) demonstrate that high-dose NMN modulates tumor metabolic pathways in preclinical lung adenocarcinoma models, including ferroptosis-linked effects. These findings are model-specific and no clinical trial of NMN or NR has produced an oncogenic signal in humans.18
A 2026 meta-analysis found a small reduction in diastolic blood pressure with NMN across pooled randomized trials, with no consistent systolic effect and limited clinical magnitude, findings the authors characterize as requiring large-scale confirmation. NR has been evaluated in Parkinson's disease cohorts without serious safety concerns, though sample sizes remain small and follow-up duration limited.
Existing trials include medicated participants without major safety deviations, but formal interaction data with cardiovascular, neurological, or post-stroke medications remains absent.
Current evidence supports short-term tolerability of both compounds at studied doses. Long-term safety, disease-specific risk, and interaction profiles remain unresolved.
Regulatory status in the United States
Both NMN and NR are currently marketed as dietary supplements in the United States, although their regulatory paths have differed.
NR has maintained consistent dietary supplement status, supported by early safety evaluations and regulatory pathways such as GRAS determinations and New Dietary Ingredient notifications. NMN was temporarily excluded from supplement eligibility after the FDA determined that it had been authorized for investigation as a drug before being marketed as a supplement, under the drug preclusion clause of the Dietary Supplement Health and Education Act (DSHEA), limiting commercial availability until it returned to dietary supplement eligibility.
These regulatory differences reflect classification decisions rather than differences in safety, effectiveness, or biological function. As of now, both compounds are legally available as dietary supplements in the United States.
NMN vs NR comparison table
| Compound | Mechanism to NAD+ | Human evidence | Bioavailability notes | Regulatory status |
|---|---|---|---|---|
| NMN | NMN is converted to NAD+ via NMNAT enzymes in the NAD+ salvage pathway; NMN can also be converted to NR before entering the same pathway | Increases circulating NAD+ in human studies; functional outcomes (energy, cognition, metabolic markers) remain inconsistent across trials; no superiority over NR demonstrated | Oral NMN increases blood NAD+ levels in humans; systemic exposure is comparable to NR in available studies; no established bioavailability advantage | Dietary supplement (United States) |
| NR | NR is phosphorylated by nicotinamide riboside kinases (NRK1/NRK2) → NMN → NAD+ via NMNAT in the NAD+ salvage pathway | Increases circulating NAD+ in human studies; functional outcomes remain inconsistent across trials; no superiority over NMN demonstrated | Oral NR reliably increases blood NAD+ levels in humans; systemic exposure is comparable to NMN in available studies; no established bioavailability advantage | Dietary supplement (United States) |
Cost and availability differences
NMN and NR differ in cost and availability due to differences in manufacturing scale, regulatory stability, and supply chain maturity. NR has a more established manufacturing infrastructure, supporting consistent large-scale production and stable global distribution. This contributes to relatively predictable pricing patterns within the higher but stable end of the supplement market.
NMN demonstrates greater variability in both availability and cost structure, particularly following periods of regulatory reassessment in the United States that affected product continuity and market access. As a result, pricing tends to be more variable across manufacturers, reflecting differences in sourcing, formulation quality, and supply chain stability.
Across both compounds, NMN is more frequently subject to price fluctuation, while NR shows greater pricing stability due to more mature commercial infrastructure. In both cases, cost is driven primarily by manufacturing consistency, brand standardization, and regulatory certainty, not differences in clinical efficacy.
Use case differences in real-world context
There are no established differences in clinical outcomes between NMN and NR, so their use in practice is guided by other factors such as regulatory context, supply chain stability, formulation consistency, and practical accessibility, with both compounds functioning largely as interchangeable NAD+ precursors in practice.
NR is distinguished by a more stable regulatory and commercial trajectory and a consolidated manufacturing landscape, which supports more consistent product standardization across research and commercial formulations. Its human trial record spans cardiovascular, neurological, and musculoskeletal populations, providing broader contextual reference points for safety and pharmacokinetic behavior in applied settings.
NMN has experienced greater regulatory fluctuation but remains widely available following reinstatement under dietary supplement frameworks, with an expanding human evidence base in metabolic and physical performance populations. However, greater variability in manufacturing consistency introduces heterogeneity in real-world product reliability across suppliers.
Selection is ultimately determined less by mechanistic differences and more by external constraints that shape usability, including regulatory certainty, verified product quality, and sustained dosing feasibility within clinically studied ranges. Neither compound is supported for use based on marketing claims that extend beyond current human evidence.
Where NMN and NR fit in a broader longevity approach
NMN and NR belong in the adjunctive layer of longevity care, positioned after foundational interventions and before any claim of meaningful clinical impact. Their primary value lies in increasing NAD+ availability and engaging biological pathways linked to cellular maintenance.
Both compounds support processes involved in cellular energy production, mitochondrial function, and DNA repair, which explains their scientific appeal. Human studies have consistently confirmed NAD+ elevation, but this has not translated into reliable improvements in functional aging outcomes such as physical performance, cognitive health, or disease progression.
Physical activity, metabolic health, nutritional adequacy, and sleep regulation remain the interventions with the strongest evidence for improving long-term outcomes. NMN and NR may contribute within that broader framework, but their role remains supportive until longer-term human data demonstrate measurable clinical benefit. For broader context on the full landscape, see our review of evidence-based longevity supplements, and for a deeper look at NAD+ precursors specifically, see are NAD+ supplements actually worth it?
Common misconceptions about NMN and NR
NMN and NR reliably increase NAD+ levels in human studies, but these biochemical changes have not translated into consistent improvements in physical function, cognition, metabolic health, or subjective energy. Comparative human data show similar NAD+ responses between both compounds, with no demonstrated advantage of one over the other in measured clinical outcomes.
The magnitude of NAD+ elevation also does not predict the degree of functional change, as higher biomarker levels have not been associated with proportionate improvements across trials. Short-term supplementation has not produced reliable immediate effects on fatigue, energy, or performance under controlled conditions.
The central limitation in current interpretation is not uncertainty about the underlying mechanism, but the assumption that restoring NAD+ alone is sufficient to produce measurable clinical benefit.
Quality and supplement variability
Commercial NMN and NR products vary in purity, dose accuracy, and manufacturing standards, with analytical testing reports suggesting differences between labeled and measured NMN content across suppliers. This is clinically relevant because products that do not reflect studied doses cannot be expected to reproduce research outcomes.
NR is generally produced under more standardized manufacturing systems because it has been developed and supplied more consistently as a single defined ingredient, which leads to more uniform product quality across brands. NMN shows greater variability due to less centralized sourcing, making third-party lab reports that verify purity and dose accuracy important when evaluating product quality.
Clinical perspective
The NAD+ precursor field is supported by a clear mechanistic basis, a reassuring short-term safety profile, and consistent biomarker responses in human studies. What remains unresolved is the translation of these biochemical changes into clinically meaningful outcomes.
Elevation of circulating NAD+ does not directly reflect restoration of NAD+-dependent processes within specific tissues affected by aging. The brain, heart, skeletal muscle, and other metabolically active organs differ in enzyme expression, transport dynamics, and NAD+ turnover, which are not captured by systemic measures alone. As a result, current biomarkers do not fully represent tissue-level activity or functional recovery.
This limits interpretation of existing trials, which are generally short in duration and not designed to assess long-term physiological adaptation. Addressing this gap requires longer-duration studies with tissue-relevant endpoints, adequately powered head-to-head comparisons, and population stratification in line with metabolic and biological variability.
With the current evidence base, NMN and NR can be described as compounds that reliably modify NAD+ biomarkers without established consistency in functional outcomes. Whether this biochemical effect translates into clinically meaningful benefit remains undetermined, and that uncertainty defines the current state of the literature.
Bottom line
Both NMN and NR reliably increase NAD+ biomarkers in humans through the same metabolic pathway, and current evidence does not demonstrate a meaningful clinical advantage for either compound. The observed biochemical response has not consistently translated into functional health outcomes, and this gap between a reproducible biomarker effect and established clinical benefit defines the current state of the evidence.
Frequently asked questions
Is NMN better than NR for aging?
No. Both compounds increase NAD+ comparably in human trials, and neither has demonstrated superior aging-related outcomes over the other.
Does NMN absorb better than NR?
Not based on current evidence. Both produce comparable increases in circulating NAD+, with no meaningful difference in overall bioavailability established between them.
Why was NMN harder to find?
NMN became harder to find after the FDA determined in 2022 that it was excluded from dietary supplement status under the drug preclusion clause. In September 2025, the FDA reversed course and concluded NMN was not excluded from the dietary supplement definition, although companies may still need to comply with New Dietary Ingredient requirements.
Can NMN and NR be taken together?
No added benefit has been demonstrated. No human trial has evaluated the combination, and both compounds enter the same NAD+ biosynthetic pathway.
Should NAD+ levels be tested before supplementing?
Not routinely. No validated thresholds currently link a measured NAD+ level to a supplementation decision, making baseline testing of limited practical value for most people.
Are there natural ways to support NAD+?
Yes. Physical activity, adequate sleep, and dietary intake of niacin and tryptophan support natural NAD+ production and currently carry stronger evidence for health benefits than either compound.
References
- Yoshino J, Baur JA, Imai SI. NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018 Mar 6;27(3):513-528. doi: 10.1016/j.cmet.2017.11.002. PMID: 29249689.
- Grozio A, Mills KF, Yoshino J, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nat Metab. 2019 Jan;1(1):47-57. doi: 10.1038/s42255-018-0009-4. PMID: 31131364.
- McReynolds MR, Chellappa K, Baur JA. Age-related NAD+ decline. Exp Gerontol. 2020 Jun;134:110888. doi: 10.1016/j.exger.2020.110888. PMID: 32097708.
- Christen S, Redeuil K, Goulet L, et al. The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans. Nat Metab. 2026 Jan;8(1):62-73. PMID: 41540253.
- Berven H, Svensen M, Eikeland H, et al. The NAD-brain pharmacokinetic study of NAD augmentation in blood and brain using oral precursor supplementation. iScience. 2026 Jan 27;29(3):114764. PMID: 41858901.
- Yi L, Maier AB, Tao R, et al. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults. Geroscience. 2023 Feb;45(1):29-43. PMID: 36482258.
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021 Jun 11;372(6547):1224-1229. PMID: 33888596.
- Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018 Mar 29;9(1):1286. PMID: 29599478.
- Elhassan YS, Kluckova K, Fletcher RS, et al. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures. Cell Rep. 2019 Aug 13;28(7):1717-1728.e6. PMID: 31412242.
- Orr ME, Kotkowski E, Ramirez P, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. Geroscience. 2024 Feb;46(1):665-682. PMID: 37994989.
- Wu CY, Reynolds WC, Abril I, et al. Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. EClinicalMedicine. 2025 Nov 12;89:103633. PMID: 41357333.
- Ratajczak J, Joffraud M, Trammell SA, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016 Oct 11;7:13103. PMID: 27725675.
- Tarantini S, Valcarcel-Ares MN, Toth P, et al. Nicotinamide mononucleotide (NMN) supplementation rescues cerebromicrovascular endothelial function and neurovascular coupling responses and improves cognitive function in aged mice. Redox Biol. 2019 Jun;24:101192. PMID: 31015147.
- Ramanathan C, Lackie T, Williams DH, et al. Oral Administration of Nicotinamide Mononucleotide Increases Nicotinamide Adenine Dinucleotide Level in an Animal Brain. Nutrients. 2022 Jan 12;14(2):300. PMID: 35057482.
- Wang P, Li JX, Kong YY, et al. Nicotinamide Mononucleotide and Nicotinamide Riboside Improve Dyslipidemia and Fatty Liver but Promote Atherosclerosis in Apolipoprotein E Knockout Mice. Pharmaceuticals (Basel). 2025 Feb 20;18(3):281. PMID: 40143060.
- Okabe K, Yaku K, Uchida Y, et al. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. Front Nutr. 2022 Apr 11;9:868640. PMID: 35479740.
- Hwang ES, Song SB. Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment. Biomolecules. 2020 Apr 29;10(5):687. PMID: 32365524.
- Zhang M, Cui J, Chen H, et al. High-Dosage NMN Promotes Ferroptosis to Suppress Lung Adenocarcinoma Growth through the NAM-Mediated SIRT1-AMPK-ACC Pathway. Cancers (Basel). 2023 Apr 23;15(9):2427. PMID: 37173894.